Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

Dr Pradeep highlights warning signs of heart failure, including increased urination at night, swollen ankles, and ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

Ultromics, a pioneer in AI-driven cardiology solutions, today announced an investment from the American Heart Association's Go Red for Women Venture Fund, a fund within American Heart Association ...

Once largely a diagnosis of exclusion, new tools and treatments are unraveling some of the mysteries surrounding heart failure with preserved ejection fraction.

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

NEW YORK CITY — A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn't benefit the vast majority of patients and may contribute to a higher ...

Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced. The nonsteroidal mineralocorticoid receptor antagonist (MRA) is the first of its ...

SEATTLE — Aaron Boone and Mark Wegner were screaming face to face, close enough to smell the dinner on each other’s breath. The New York Yankees manager and the home plate umpire went at it for nearly ...

The new T-7A Red Hawk ejection system passes high-speed test at Holloman Air Force Base, New Mexico. After coming under scrutiny for serious ejection system deficiencies identified during earlier ...